Portola Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Portola Pharmaceuticals Inc.
Vanguard Health Care Fund
2,913,937
4.41%
0
0.17%
06/30/2018
SPDR S&P Biotech ETF
1,714,080
2.59%
4,410
0.87%
09/06/2018
Vanguard Small Cap Index Fund
1,654,555
2.5%
19,243
0.05%
07/31/2018
Vanguard Total Stock Market Index Fund
1,645,056
2.49%
9,892
0.01%
07/31/2018
iShares Russell 2000 ETF
1,361,470
2.06%
-726
0.08%
09/06/2018
Vanguard Small Cap Growth Index Fund
945,911
1.43%
13,515
0.11%
07/31/2018
Wellington Mgmt. Port (Dublin) Plc - Global Health Care Eq.
924,676
1.4%
-10,324
1.28%
12/31/2017
Fidelity Select Biotechnology Portfolio
904,003
1.37%
-22,800
0.28%
07/31/2018
Vanguard Extended Market Index Fund
870,857
1.32%
9,100
0.04%
07/31/2018
iShares Nasdaq Biotechnology ETF
762,936
1.14%
-9,975
0.23%
09/06/2018
| Address |
270 East Grand Avenue
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.portola.com |
| Updated |
07/08/2019 |
| Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation. Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation factor Xa (recombinant), inactivated-zhzo, the antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company was founded by Charles J. |
